Extract from the Register of European Patents

EP About this file: EP3960164

EP3960164 - METHOD FOR PRODUCING PHARMACEUTICAL FORMULATION [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  01.12.2023
Database last updated on 21.03.2026
FormerRequest for examination was made
Status updated on  28.01.2022
FormerThe international publication has been made
Status updated on  31.10.2020
Most recent event   Tooltip01.12.2023Application deemed to be withdrawnpublished on 03.01.2024  [2024/01]
Applicant(s)For all designated states
Nipro Corporation
9-3, Honjo-nishi 3-chome
Kita-ku
Osaka-shi, Osaka 531-8510 / JP
[2022/09]
Inventor(s)01 / NAKANO Yoshio
c/o NIPRO CORPORATION, 9-3, Honjo-nishi 3-chome
Kita-ku
Osaka-shi, Osaka 531-8510 / JP
02 / HAYASHIDA Tomohiro
c/o NIPRO CORPORATION, 9-3, Honjo-nishi 3-chome
Kita-ku
Osaka-shi, Osaka 531-8510 / JP
03 / HOASHI Yohei
c/o NIPRO CORPORATION, 9-3, Honjo-nishi 3-chome
Kita-ku
Osaka-shi, Osaka 531-8510 / JP
04 / EDAMURA Keisuke
c/o NIPRO CORPORATION, 9-3, Honjo-nishi 3-chome
Kita-ku
Osaka-shi, Osaka 531-8510 / JP
05 / ICHIKAWA Yuki
c/o NIPRO CORPORATION, 9-3, Honjo-nishi 3-chome
Kita-ku
Osaka-shi, Osaka 531-8510 / JP
 [2022/09]
Representative(s)Reitstötter Kinzebach
Patentanwälte
Sternwartstraße 4
81679 München / DE
[N/P]
Former [2022/09]Reitstötter Kinzebach
Patentanwälte
Sternwartstrasse 4
81679 München / DE
Application number, filing date20795882.821.04.2020
[2022/09]
WO2020JP17254
Priority number, dateJP2019008137222.04.2019         Original published format: JP 2019081372
[2022/09]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020218310
Date:29.10.2020
Language:JA
[2020/44]
Type: A1 Application with search report 
No.:EP3960164
Date:02.03.2022
Language:EN
[2022/09]
Search report(s)International search report - published on:JP29.10.2020
(Supplementary) European search report - dispatched on:EP14.12.2022
ClassificationIPC:A61J3/06, A61J3/00, A61K9/20, A61K31/137, A61K31/519, A61K31/558, A61K9/28
[2023/02]
CPC:
A61K9/2866 (EP); A61K9/28 (US); A61J3/005 (EP);
A61K31/137 (EP,US); A61K31/519 (EP); A61K31/558 (EP);
A61K9/2013 (US); A61K9/2018 (US); A61K9/2027 (US);
A61K9/2054 (US); A61K9/2059 (US); A61K9/2086 (EP);
A61K9/2095 (EP); A61K9/0056 (EP) (-)
Former IPC [2022/09]A61K9/28, A61K9/44, A61K9/48, A61J3/06
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/09]
TitleGerman:VERFAHREN ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN FORMULIERUNG[2022/09]
English:METHOD FOR PRODUCING PHARMACEUTICAL FORMULATION[2022/09]
French:PROCÉDÉ POUR PRODUIRE UNE FORMULATION PHARMACEUTIQUE[2022/09]
Entry into regional phase22.10.2021Translation filed 
22.10.2021National basic fee paid 
22.10.2021Search fee paid 
22.10.2021Designation fee(s) paid 
22.10.2021Examination fee paid 
Examination procedure22.10.2021Examination requested  [2022/09]
06.05.2022Amendment by applicant (claims and/or description)
28.11.2022Observations by third parties
22.07.2023Application deemed to be withdrawn, date of legal effect  [2024/01]
14.08.2023Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2024/01]
Fees paidRenewal fee
29.04.2022Renewal fee patent year 03
28.04.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X] WO2005123569  (SMITHKLINE BEECHAM CORP et al.) [X] 1-20 * page 17, paragraph 88 - page 19, paragraph 92 * * page 21, paragraph 99 - page 23, paragraph 103 * * page 30, paragraph 122 - page 33, paragraph 130 * * page 41, paragraph 153 * * page 42, paragraph 157 - page 43, paragraph 158 * * page 46, paragraph 167 - page 47, paragraph 168 * * page 71, paragraphs 227-228 * * claim - *
 [X] GB2512098  (BUFTON ROLY et al.) [X] 1-8,11-18 * page 5, lines 3-31 * * page 6, line 26 - page 7, line 18 * * page 14, lines 8-23 * * page 15, line 26 - page 17, line 25 * * claim - *
 [X] US2006002986  (CLARKE ALLAN J et al.) [X] 1-20 * page 2, paragraphs 23-27 * * page 4, paragraphs 81-84 * * page 7, paragraphs 120-122 * * page 15, paragraph 206 - page 16, paragraph 209 * * page 16, paragraph 217 - page 17, paragraph 221 * * claim - *
International search[XY] JP2012254974  (XEROX CORP et al.) [X] 1-3, 5-6, 11-15, 17-18 [Y] 1-20
 [XY] JPS55108815  (THOMAE GMBH DR K) [X] 1-2, 4, 11-14, 16 [Y] 1-20
 [Y] JP2006528191   [Y] 1-20
 [Y] JP2006528192   [Y] 1-20
 [Y] WO2006126561  (EISAI R&D MAN CO LTD et al.) [Y] 1-20
 [Y] JP2017057344  (SCREEN HOLDINGS CO LTD et al.) [Y] 1-20
 [Y] WO2016117518  (QUALICAPS CO LTD et al.) [Y] 1-20
by applicantJP2006006303
 US4322449
 JP2006063030
otherJP3215836
 WO2005123569
 US2005202051
 US2019336396
 JP2016203235
 JP2016203218
 JP3215836
   NAOKO KISU ET AL.: "Particle containment in pharmaceutical equipment (Containment) Performance Evaluation", SCAS NEWS, vol. I, 1 January 2013 (2013-01-01), pages 7 - 10, XP093010466
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.